Introduksjon
Denne siden gir en grundig analyse av den kjente historikken for insidernes handelsaktiviteter for Gillian C Ivers-read. Insidere er ledere, direktører eller betydelige investorer i et selskap. Det er ulovlig for insidere å gjøre handler i deres selskaper basert på spesifikke, ikke-offentlig informasjon. Dette betyr ikke at det er ulovlig for dem å gjøre noen handler i deres egne selskaper. Imidlertid må de rapportere alle handler til SEC via et skjema 4. Til tross for disse begrensningene, antyder akademisk forskning at insidere - generelt sett - har en tendens til å overgå markedet i sine egne selskaper.
Gjennomsnittlig handelslønnsomhet
Den gjennomsnittlige handelslønnsomheten er den gjennomsnittlige avkastningen av alle åpne markedskjøp gjort av insideren de siste tre årene. For å beregne dette, undersøker vi hvert eneste åpne marked, uplanlagte kjøp som er gjort av insideren, men dette inkluderer ikke alle handler som ble markert som en del av en 10b5-1 handelsplan. Vi beregner deretter gjennomsnittlig ytelse av disse handlene over 3, 6 og 12 måneder, gjennomsnittlig hver av disse varighetene for å generere en endelig ytelsesmåling for hver handel. Til slutt,
Dersom lønnsomheten for denne interne handelen er "N/A", har enten den interne personen ikke gjort noen åpen-markeds kjøp de siste tre årene, eller så er handlene for nylig til å beregne en pålitelig prestasjonsmåler.
Oppdateringsfrekvens: Daglig
Selskaper med rapporterte insiderposisjoner
SEC-arkiveringene indikerer at Gillian C Ivers-read har rapporterte beholdninger av handler i følgende selskaper:
Verdipapir | Navn | Siste rapporterte høydepunkter |
---|---|---|
US:CLVS / Clovis Oncology Inc | See Remarks | 293 612 |
US:BPTH / Bio-Path Holdings, Inc. | Director | 25 000 |
Hvordan tolke diagrammene
De følgende diagrammene viser aksjens ytelse etter hver åpen markedstransaksjon som ikke var planlagt, utført av Gillian C Ivers-read. Ikke-planlagte handler er handler som ikke ble gjort som en del av en 10b5-1 handelsplan. Aksjeytelsen er kartlagt som kumulativ prosentendring i aksjekursen. For eksempel, hvis en innsidehandel ble gjort 1. januar 2019, vil diagrammet vise daglig prosentendring for verdipapiret til dagens dato. Dersom aksjeprisen går fra $10 til $15 i løpet av denne tiden, vil den kumulative prosentendringen i aksjeprisen være 50%. En endring i prisen fra $10 til $20 vil være 100%, og en endring i prisen fra $10 til $5 vil være - 50%.
Til syvende og sist er målet vårt å avgjøre hvor tett insidernes handler korrelerer med overavkastninger (positiv eller negativ) i aksjekursen for å se om insidere timer sine handler for å tjene på intern informasjon. Se for deg en situasjon der en insider gjør dette. I denne situasjonen, forventer vi enten (a) positive avkastninger etter kjøp, eller (b) negative avkastninger etter salg. I tilfelle (a) KJØP-diagrammet ville vise en serie av oppadgående kurver, som indikerer positive avkastninger etter hver kjøpstransaksjon. I tilfelle (b) ville SALG-diagrammet vise en serie av nedadgående kurver, som indikerer negative avkastninger etter hver salgstransaksjon.
Imidlertid er dette alene ikke nok til å dra konklusjoner. Hvis, for eksempel, aksjeprisen for selskapet steg jevnt over mange år uten å følge en syklisk trend, ville vi forventet at alle postkjøpsdiagrammer skal ha en stigende trend. På samme måte vil ikke-sykliske nedganger over mange år resultere i nedadgående trend i post-trade diagrammer. Ingen av disse diagrammene ville antyde aktiviteter som insidertrening.
Den sterkeste indikatoren ville vært en situasjon der aksjekursen var ekstremt syklisk, og det var både positive signaler i KJØPSdiagrammet og negative plot i SALGSdiagrammet. Denne situasjonen ville vært sterkt antydende om en insider som timet handler til sin økonomiske fordel.
Internkjøp BPTH / Bio-Path Holdings, Inc. - Analyse av kortsiktig fortjeneste
I denne seksjonen analyserer vi lønnsomheten av hvert uplanlagt, åpen-marked internsalg som er gjort i BPTH / Bio-Path Holdings, Inc.. Denne analysen hjelper til å forstå om den interne personen regelmessig genererer unormale avkastninger, og er verdt å følge. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til maks |
Pris ved maks |
Maks fortjeneste ($) |
Maks fortjeneste (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Internhandel BPTH / Bio-Path Holdings, Inc. - Analyse av kortsiktig tap
I denne seksjonen analyserer vi unngåelsen av kortsiktig tap for hvert uplanlagt, åpen-marked internsalg som er gjort i BPTH / Bio-Path Holdings, Inc.. Et jevnt mønster av tap unngåelse kan antyde at fremtidige salgstransaksjoner kan forutsi nedgang i pris. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til min |
Pris ved min |
Maks tap unngått ($) |
Maks tap unngått (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Innsidernes handelshistorikk
Tabellen viser den komplette listen over innsidehandler gjort av Gillian C Ivers-read som avslørt til Securies Exchange Comission (SEC).
Fildato | Transaksjonsdato | Skjema | Ticker | Verdipapir | Kode | Aksjer | Gjenværende aksjer | Prosent endring |
Aksje pris |
Transaksjons verdi |
Gjenværende verdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2022-11-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −2 006 | 293 612 | −0,68 | 0,98 | −1 972 | 288 591 | |
2022-11-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −1 675 | 290 993 | −0,57 | 0,98 | −1 646 | 286 017 | |
2022-11-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 4 625 | 295 618 | 1,59 | ||||
2022-11-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 3 749 | 292 668 | 1,30 | ||||
2022-09-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −2 234 | 288 919 | −0,77 | 1,20 | −2 681 | 346 703 | |
2022-09-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 5 063 | 291 153 | 1,77 | ||||
2022-08-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −2 100 | 286 090 | −0,73 | 1,46 | −3 068 | 417 977 | |
2022-08-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −1 702 | 283 565 | −0,60 | 1,46 | −2 487 | 414 288 | |
2022-08-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 4 625 | 288 190 | 1,63 | ||||
2022-08-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 3 749 | 285 267 | 1,33 | ||||
2022-06-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −2 327 | 281 518 | −0,82 | 0,64 | −1 495 | 180 847 | |
2022-06-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 5 062 | 283 845 | 1,82 | ||||
2022-05-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −2 062 | 278 783 | −0,73 | 1,97 | −4 062 | 549 147 | |
2022-05-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −1 671 | 276 220 | −0,60 | 1,97 | −3 292 | 544 098 | |
2022-05-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −4 625 | 32 375 | −12,50 | ||||
2022-05-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −3 749 | 11 248 | −25,00 | ||||
2022-05-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 4 625 | 280 845 | 1,67 | ||||
2022-05-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 3 749 | 277 891 | 1,37 | ||||
2022-03-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −10 416 | 274 142 | −3,66 | 1,87 | −19 436 | 511 549 | |
2022-03-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −354 | 264 308 | −0,13 | 1,87 | −661 | 493 199 | |
2022-03-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | 688 | 0 | −100,00 | ||||
2022-03-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | 20 250 | 60 750 | 50,00 | ||||
2022-03-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
A - Award | 81 000 | 81 000 | |||||
2022-03-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 20 250 | 284 558 | 7,66 | ||||
2022-03-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 688 | 264 662 | 0,26 | ||||
2022-02-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −2 453 | 263 974 | −0,92 | 1,94 | −4 758 | 512 057 | |
2022-02-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −1 989 | 261 802 | −0,75 | 1,94 | −3 858 | 507 791 | |
2022-02-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −4 625 | 37 000 | −11,11 | ||||
2022-02-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −3 750 | 14 997 | −20,00 | ||||
2022-02-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 4 625 | 266 427 | 1,77 | ||||
2022-02-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 3 750 | 263 791 | 1,44 | ||||
2021-12-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −304 | 260 041 | −0,12 | 3,00 | −912 | 780 123 | |
2021-12-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −687 | 688 | −49,96 | ||||
2021-12-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 687 | 260 345 | 0,26 | ||||
2021-11-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −2 041 | 259 658 | −0,78 | 4,55 | −9 287 | 1 181 444 | |
2021-11-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −1 655 | 257 074 | −0,64 | 4,55 | −7 530 | 1 169 687 | |
2021-11-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −4 625 | 41 625 | −10,00 | ||||
2021-11-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −3 749 | 18 747 | −16,67 | ||||
2021-11-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 4 625 | 261 699 | 1,80 | ||||
2021-11-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 3 749 | 258 729 | 1,47 | ||||
2021-09-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −304 | 254 980 | −0,12 | 4,89 | −1 487 | 1 246 852 | |
2021-09-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −688 | 1 375 | −33,35 | ||||
2021-09-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 688 | 255 284 | 0,27 | ||||
2021-08-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −2 034 | 254 596 | −0,79 | 4,82 | −9 804 | 1 227 153 | |
2021-08-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −1 649 | 252 005 | −0,65 | 4,82 | −7 948 | 1 214 664 | |
2021-08-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −4 625 | 46 150 | −9,11 | ||||
2021-08-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −3 749 | 22 496 | −14,28 | ||||
2021-08-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 4 625 | 256 630 | 1,84 | ||||
2021-08-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 3 749 | 253 654 | 1,50 | ||||
2021-06-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −283 | 249 905 | −0,11 | 5,63 | −1 593 | 1 406 965 | |
2021-06-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | 687 | 2 063 | 49,93 | ||||
2021-06-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 687 | 250 188 | 0,28 | ||||
2021-05-04 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −2 183 | 249 501 | −0,87 | 5,54 | −12 094 | 1 382 236 | |
2021-05-04 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −1 769 | 247 059 | −0,71 | 5,54 | −9 800 | 1 368 707 | |
2021-05-04 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −4 625 | 50 875 | −8,33 | ||||
2021-05-04 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −3 749 | 26 245 | −12,50 | ||||
2021-05-04 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 4 625 | 251 684 | 1,87 | ||||
2021-05-04 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 3 749 | 248 828 | 1,53 | ||||
2021-03-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −304 | 245 079 | −0,12 | 6,29 | −1 912 | 1 541 547 | |
2021-03-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −276 | 244 695 | −0,11 | 6,29 | −1 736 | 1 539 132 | |
2021-03-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | 688 | 2 750 | 33,37 | ||||
2021-03-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | 625 | 0 | −100,00 | ||||
2021-03-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
A - Award | 81 000 | 81 000 | |||||
2021-03-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 688 | 245 383 | 0,28 | ||||
2021-03-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 625 | 244 971 | 0,26 | ||||
2021-02-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −9 031 | 244 346 | −3,56 | 7,97 | −71 977 | 1 947 438 | |
2021-02-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −1 959 | 234 877 | −0,83 | 7,97 | −15 613 | 1 871 970 | |
2021-02-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −18 500 | 55 500 | −25,00 | ||||
2021-02-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −3 750 | 29 994 | −11,11 | ||||
2021-02-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 18 500 | 253 377 | 7,88 | ||||
2021-02-03 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 3 750 | 236 836 | 1,61 | ||||
2020-12-23 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −1 875 | 0 | −100,00 | ||||
2020-12-23 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −829 | 233 086 | −0,35 | 5,68 | −4 709 | 1 323 928 | |
2020-12-23 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 1 875 | 233 915 | 0,81 | ||||
2020-12-14 |
|
4 | CLVS |
Clovis Oncology, Inc.
Employee Stock Option (right to buy) |
M - Exercise | −68 965 | 0 | −100,00 | ||||
2020-12-14 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
F - Taxes | −52 447 | 232 040 | −18,44 | 4,81 | −252 270 | 1 116 112 | |
2020-12-14 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 68 965 | 284 487 | 32,00 | 3,28 | 226 205 | 933 117 | |
2020-12-07 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −687 | 3 438 | −16,65 | ||||
2020-12-07 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −625 | 625 | −50,00 | ||||
2020-12-07 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −304 | 215 522 | −0,14 | 4,89 | −1 487 | 1 053 903 | |
2020-12-07 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 687 | 215 826 | 0,32 | ||||
2020-12-07 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −277 | 215 139 | −0,13 | 4,89 | −1 355 | 1 052 030 | |
2020-12-07 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 625 | 215 416 | 0,29 | ||||
2020-11-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −3 749 | 33 744 | −10,00 | ||||
2020-11-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −1 689 | 214 791 | −0,78 | 4,93 | −8 327 | 1 058 920 | |
2020-11-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 3 749 | 216 480 | 1,76 | ||||
2020-09-23 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −1 875 | 1 875 | −50,00 | ||||
2020-09-23 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −829 | 212 731 | −0,39 | 6,85 | −5 679 | 1 457 207 | |
2020-09-23 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −9 | 213 560 | 0,00 | 6,86 | −62 | 1 465 022 | |
2020-09-23 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 1 875 | 213 569 | 0,89 | ||||
2020-09-08 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −688 | 4 125 | −14,29 | ||||
2020-09-08 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −625 | 1 250 | −33,33 | ||||
2020-09-08 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −290 | 211 694 | −0,14 | 5,30 | −1 537 | 1 121 978 | |
2020-09-08 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 688 | 211 984 | 0,33 | ||||
2020-09-08 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −263 | 211 296 | −0,12 | 5,30 | −1 394 | 1 119 869 | |
2020-09-08 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 625 | 211 559 | 0,30 | ||||
2020-08-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −3 749 | 37 493 | −9,09 | ||||
2020-08-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −1 670 | 210 934 | −0,79 | 5,92 | −9 886 | 1 248 729 | |
2020-08-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 3 749 | 212 604 | 1,80 | ||||
2020-06-23 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −1 875 | 3 750 | −33,33 | ||||
2020-06-23 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −829 | 208 855 | −0,40 | 6,74 | −5 587 | 1 407 683 | |
2020-06-23 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 1 875 | 209 684 | 0,90 | ||||
2020-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −687 | 4 813 | −12,49 | ||||
2020-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −625 | 1 875 | −25,00 | ||||
2020-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −313 | 207 809 | −0,15 | 7,03 | −2 200 | 1 460 897 | |
2020-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 687 | 208 122 | 0,33 | ||||
2020-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −285 | 207 435 | −0,14 | 7,03 | −2 004 | 1 458 268 | |
2020-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 625 | 207 720 | 0,30 | ||||
2020-05-07 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −3 749 | 41 242 | −8,33 | ||||
2020-05-07 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −1 475 | 207 095 | −0,71 | 8,10 | −11 948 | 1 677 470 | |
2020-05-07 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 3 749 | 208 570 | 1,83 | ||||
2020-03-23 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −1 875 | 5 625 | −25,00 | ||||
2020-03-23 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −829 | 204 821 | −0,40 | 4,60 | −3 813 | 942 177 | |
2020-03-23 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 1 875 | 205 650 | 0,92 | ||||
2020-03-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −688 | 5 500 | −11,12 | ||||
2020-03-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −625 | 2 500 | −20,00 | ||||
2020-03-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −317 | 203 775 | −0,16 | 7,20 | −2 282 | 1 467 180 | |
2020-03-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 688 | 204 092 | 0,34 | ||||
2020-03-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −288 | 203 404 | −0,14 | 7,20 | −2 074 | 1 464 509 | |
2020-03-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 625 | 203 692 | 0,31 | ||||
2020-02-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −14 997 | 44 991 | −25,00 | ||||
2020-02-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −7 204 | 203 067 | −3,43 | 8,41 | −60 586 | 1 707 793 | |
2020-02-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 14 997 | 210 271 | 7,68 | ||||
2020-01-31 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
A - Award | 74 000 | 74 000 | |||||
2019-12-26 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −1 875 | 7 500 | −20,00 | ||||
2019-12-26 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −830 | 195 274 | −0,42 | 11,30 | −9 379 | 2 206 596 | |
2019-12-26 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 1 875 | 196 104 | 0,97 | ||||
2019-12-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −687 | 6 188 | −9,99 | ||||
2019-12-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −625 | 3 125 | −16,67 | ||||
2019-12-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −310 | 194 229 | −0,16 | 14,59 | −4 523 | 2 833 801 | |
2019-12-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 687 | 194 539 | 0,35 | ||||
2019-12-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −282 | 193 852 | −0,15 | 14,60 | −4 117 | 2 830 239 | |
2019-12-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 625 | 194 134 | 0,32 | ||||
2019-09-24 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −1 875 | 9 375 | −16,67 | ||||
2019-09-24 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −837 | 193 509 | −0,43 | 4,80 | −4 018 | 928 843 | |
2019-09-24 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 1 875 | 194 346 | 0,97 | ||||
2019-09-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −688 | 6 875 | −9,10 | ||||
2019-09-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −625 | 3 750 | −14,29 | ||||
2019-09-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −330 | 192 471 | −0,17 | 5,21 | −1 719 | 1 002 774 | |
2019-09-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 688 | 192 801 | 0,36 | ||||
2019-09-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −300 | 192 113 | −0,16 | 5,21 | −1 563 | 1 000 909 | |
2019-09-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 625 | 192 413 | 0,33 | ||||
2019-06-24 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −1 875 | 11 250 | −14,29 | ||||
2019-06-24 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −829 | 191 788 | −0,43 | 14,70 | −12 186 | 2 819 284 | |
2019-06-24 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 1 875 | 192 617 | 0,98 | ||||
2019-06-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −687 | 7 563 | −8,33 | ||||
2019-06-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −625 | 4 375 | −12,50 | ||||
2019-06-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −302 | 190 742 | −0,16 | 15,07 | −4 551 | 2 874 482 | |
2019-06-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 687 | 191 044 | 0,36 | ||||
2019-06-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −275 | 190 357 | −0,14 | 15,07 | −4 144 | 2 868 680 | |
2019-06-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 625 | 190 632 | 0,33 | ||||
2019-03-21 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −1 875 | 13 125 | −12,50 | ||||
2019-03-21 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −830 | 190 007 | −0,43 | 26,13 | −21 688 | 4 964 883 | |
2019-03-21 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 1 875 | 190 837 | 0,99 | ||||
2019-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −2 750 | 8 250 | −25,00 | ||||
2019-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −625 | 5 000 | −11,11 | ||||
2019-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −1 295 | 188 962 | −0,68 | 29,29 | −37 931 | 5 534 697 | |
2019-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 2 750 | 190 257 | 1,47 | ||||
2019-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −316 | 187 507 | −0,17 | 29,29 | −9 256 | 5 492 080 | |
2019-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 625 | 187 823 | 0,33 | ||||
2019-02-04 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
A - Award | 59 988 | 59 988 | |||||
2019-02-04 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (right to buy) |
A - Award | 19 996 | 19 996 | |||||
2018-12-26 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −1 875 | 15 000 | −11,11 | ||||
2018-12-26 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −829 | 187 198 | −0,44 | 17,72 | −14 690 | 3 317 149 | |
2018-12-26 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 1 875 | 188 027 | 1,01 | ||||
2018-12-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −625 | 5 625 | −10,00 | ||||
2018-12-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −250 | 186 152 | −0,13 | 21,23 | −5 308 | 3 952 007 | |
2018-12-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 625 | 186 402 | 0,34 | ||||
2018-09-24 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −1 875 | 16 875 | −10,00 | ||||
2018-09-24 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
F - Taxes | −829 | 185 777 | −0,44 | 32,21 | −26 702 | 5 983 877 | |
2018-09-24 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 1 875 | 186 606 | 1,01 | ||||
2018-09-07 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −625 | 6 250 | −9,09 | ||||
2018-09-07 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
F - Taxes | −282 | 184 731 | −0,15 | 35,75 | −10 082 | 6 604 133 | |
2018-09-07 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 625 | 185 013 | 0,34 | ||||
2018-06-21 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −1 875 | 18 750 | −9,09 | ||||
2018-06-21 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
F - Taxes | −829 | 184 388 | −0,45 | 45,75 | −37 927 | 8 435 751 | |
2018-06-21 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 1 875 | 185 217 | 1,02 | ||||
2018-06-08 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −625 | 6 875 | −8,33 | ||||
2018-06-08 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
F - Taxes | −278 | 183 342 | −0,15 | 47,70 | −13 261 | 8 745 413 | |
2018-06-08 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 625 | 183 620 | 0,34 | ||||
2018-03-21 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −1 875 | 20 625 | −8,33 | ||||
2018-03-21 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
F - Taxes | −829 | 182 995 | −0,45 | 56,75 | −47 046 | 10 384 966 | |
2018-03-21 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 1 875 | 183 824 | 1,03 | ||||
2018-03-07 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −2 500 | 7 500 | −25,00 | ||||
2018-03-07 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
F - Taxes | −1 122 | 181 949 | −0,61 | 58,43 | −65 558 | 10 631 280 | |
2018-03-07 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 2 500 | 183 071 | 1,38 | ||||
2018-03-02 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (right to buy) |
A - Award | 11 000 | 11 000 | |||||
2018-03-02 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
A - Award | 11 000 | 11 000 | |||||
2018-02-16 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −3 000 | 180 571 | −1,63 | 54,09 | −162 270 | 9 767 085 | |
2018-01-17 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −3 000 | 183 571 | −1,61 | 59,16 | −177 480 | 10 860 060 | |
2017-12-21 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
M - Exercise | −7 500 | 22 500 | −25,00 | ||||
2017-12-21 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
F - Taxes | −3 512 | 186 571 | −1,85 | 63,80 | −224 066 | 11 903 230 | |
2017-12-21 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
M - Exercise | 7 500 | 190 083 | 4,11 | ||||
2017-12-18 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −3 000 | 182 583 | −1,62 | 64,16 | −192 480 | 11 714 525 | |
2017-11-16 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −3 000 | 185 583 | −1,59 | 63,70 | −191 100 | 11 821 637 | |
2017-10-17 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −3 000 | 188 583 | −1,57 | 84,54 | −253 620 | 15 942 807 | |
2017-09-18 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −3 000 | 191 583 | −1,54 | 69,50 | −208 500 | 13 315 018 | |
2017-08-15 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −3 000 | 194 583 | −1,52 | 70,05 | −210 150 | 13 630 539 | |
2017-07-17 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −3 000 | 197 583 | −1,50 | 91,56 | −274 680 | 18 090 699 | |
2017-06-15 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −3 000 | 200 583 | −1,47 | 61,82 | −185 460 | 12 400 041 | |
2017-05-15 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −3 000 | 203 583 | −1,45 | 47,39 | −142 170 | 9 647 798 | |
2017-04-17 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −3 000 | 206 583 | −1,43 | 56,02 | −168 060 | 11 572 780 | |
2017-03-28 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
A - Award | 10 000 | 10 000 | |||||
2017-03-28 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (right to buy) |
A - Award | 20 000 | 20 000 | |||||
2017-03-15 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −3 000 | 209 583 | −1,41 | 66,99 | −200 970 | 14 039 965 | |
2016-12-19 |
|
4 | CLVS |
Clovis Oncology, Inc.
Restricted Stock Units |
A - Award | 30 000 | 30 000 | |||||
2016-09-19 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (right to buy) |
J - Other | −8 750 | 26 250 | −25,00 | ||||
2015-10-16 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −3 000 | 212 583 | −1,39 | 91,91 | −275 730 | 19 538 504 | |
2015-09-22 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | −3 000 | 215 583 | −1,37 | 112,56 | −337 680 | 24 266 022 | |
2015-03-04 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (right to buy) |
A - Award | 35 000 | 35 000 | |||||
2014-04-28 |
|
4 | BPTH |
BIO-PATH HOLDINGS INC
Stock Option |
A - Award | 25 000 | 25 000 | |||||
2014-01-14 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (right to buy) |
A - Award | 70 000 | 70 000 | |||||
2013-04-26 |
|
4 | BPTH |
BIO-PATH HOLDINGS INC
Stock Option |
A - Award | 25 000 | 25 000 | |||||
2013-03-04 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (right to buy) |
A - Award | 75 000 | 75 000 | |||||
2013-02-21 |
|
4 | BPTH |
BIO-PATH HOLDINGS INC
Stock Option |
A - Award | 25 000 | 25 000 | |||||
2012-03-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (right to buy) |
A - Award | 50 000 | 50 000 |